Purpose Amplification and high levels of NOTCH ligand expression have been identified in several types of pediatric brain tumors. A phase I trial of weekly MK-0752, an oral inhibitor of gamma-secretase, was conducted in children with recurrent central nervous system (CNS) malignancies to estimate the maximum tolerated dose, dose-limiting toxicities (DLT), pharmacokinetics (PK), and pharmacodynamics of weekly MK-0752. Methods MK-0752 was administered once weekly at 1000 and 1400 mg/m 2 using a rolling-6 design. PK analysis was performed during the first course. NOTCH and HES expression was assessed by immunohistochemistry and Western blot. Results Ten eligible patients were enrolled (median age 8.8 years; range 3.1-19.2) with diagnoses of brain stem glioma (n=3), ependymoma (n=2), anaplastic astrocytoma (n= 1), choroid plexus carcinoma (n=2), medulloblastoma (n=1), and primitive neuroectodermal tumor (n =1). Nine were evaluable for toxicity. One DLT of fatigue occurred in the six evaluable patients enrolled at 1000 mg/m 2 /dose. No DLTs were experienced by three patients treated at 1400 mg/ m 2 /dose. Non-dose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. Median number of treatment courses was 2 (range 1-10). Two patients continued on therapy for at least 6 months. The median (range) C max of MK-0752 was 88.2 μg/mL (40.6 to 109 μg/mL) and 60.3 μg/mL (59.2 to 91.9 μg/mL) in patients receiving 1000 and 1400 mg/m 2 /week, respectively. NOTCH expression was decreased in six of seven patients for whom tissue was available at 24 h post-MK-0752. Conclusion MK-0752 is well tolerated and exhibits target inhibition at 1000 and 1400 mg/m 2 /week in children with recurrent CNS malignancies.
Introduction
The NOTCH signaling pathway is a highly conserved receptor-ligand system that plays an integral role in proliferation, survival, apoptosis, and differentiation [1, 2] . Binding of NOTCH ligands (Jagged and Delta) to one of four heterodimeric transmembrane NOTCH receptors induces proteolysis by gamma-secretase, releasing the NOTCH intracellular domain (NICD) [3] . The NICD binds the CBFI/Suppressor of hairless/LAG-1 and promotes transcription of prosurvival genes, such as the hairy enhancer of split (HES) gene families [4] . The Cancer Genome Atlas project recently identified NOTCH as one of the most potentially druggable targets in human cancer [5] .
NOTCH signaling plays an important role in neural development through direct regulation of transcriptional effectors of neural stem cell proliferation and self-renewal, including SHH and Wnt [6] [7] [8] . NOTCH activation has been implicated in meningioma [9] , choroid plexus carcinoma (CPC) [10] , medulloblastoma [11] , high-grade glioma [12] , and ependymoma [13] . Specifically, recent genomic studies have identified NOTCH amplification in ∼15 % of embryonal tumors [6] and some posterior fossa ependymoma [13] ; less commonly somatic mutations of NOTCH3 and NOTCH4 have been reported in medulloblastoma [14] . NOTCH1 mutation in conjunction with loss of P53 appears sufficient to induce formation of SHH-like medulloblastoma in mice [15] . Overexpression of NOTCH receptors and ligands is commonly observed in high-grade glioma [16] . NOTCH-mediated promotion of CD133+ glioblastoma stem cells has been demonstrated in vitro and in vivo, and importantly, gammasecretase inhibition depletes this stem cell fraction and inhibits tumor growth [17] .
MK-0752, a potent oral gamma-secretase inhibitor, prevents cleavage of gamma-secretase substrates with a 50 % inhibitory concentration (IC 50 ) of 50 nmol/L [18] . MK-0752 was initially developed as a treatment for Alzheimer's disease and, in animal models, was shown to penetrate the bloodbrain barrier and reduce amyloid peptide levels by 50 %. The safety and tolerability of MK-0752 has been studied in refractory adult solid tumors [19] and in combination with docetaxel for advanced breast cancer [20] . MK-0752 toxicities are highly schedule-dependent [19] . Weekly administration was most tolerable and achieved target inhibition at 3200 mg, providing rationale to study this schedule in children.
Our group previously published a phase I study of MK-0752 in children with recurrent CNS tumors using a 3-dayson/4-days-off dosing schedule, which was well tolerated at 260 mg/m 2 [21] . We now report results of a phase I study of weekly MK-0752. The primary objective was to estimate the maximum tolerated dose (MTD) of weekly MK-0752. The secondary objectives were to describe the dose-limiting toxicities (DLTs) and plasma pharmacokinetics (PK) of weekly MK-0752, to describe NOTCH pathway protein expression in archival tumor tissue, and to assess the pharmacodynamic effects of MK-0752 on peripheral blood mononuclear cells (PBMCs).
Materials and methods

Patient eligibility
Eligible patients were >3 and ≤21 years with a Lansky or Karnofsky score ≥60 and a histologically verified recurrent malignant CNS tumor. Histology was waived for diffuse intrinsic brainstem glioma patients. Other eligibility criteria included: recovery from acute toxic effects of prior therapy; ≥3 weeks since myelosuppressive therapy; ≥7 days since growth factor (14 days if long-acting) or biologic agents; ≥6 months since craniospinal irradiation; ≥2 weeks since local palliative radiotherapy; ≥3 months since autologous bone marrow transplant; adequate bone marrow (absolute neutrophil count ≥1000/μL, platelet count ≥100,000/μL, hemoglobin ≥8.0 g/dL), renal (normal serum creatinine for age or glomerular filtration rate ≥70 mL/min/1.73 m 2 ), and liver (total bilirubin ≤1.5× and ALT ≤2.5× institutional upper limit of normal for age and albumin ≥2.5 g/dL) function. Patients on corticosteroids had to be on a stable or decreasing dose for ≥2 weeks. Pregnant or lactating females and patients on enzyme-inducing anticonvulsants or systemic anticoagulation were excluded. Patients of childbearing or child fathering potential had to agree to use birth control, including abstinence, while on study. The institutional review boards of participating institutions approved the protocol. Informed consent and assent were obtained according to local institutional guidelines.
Drug administration and study design
MK-0752 (Merck, West Point, PA), supplied as 10-, 50-, and 200-mg dry filled, hard gelatin capsules, administered orally one time each week. Each course was 28 days. The starting dosage was 1000 mg/m 2 once weekly. Other planned dose levels included 1400 and 1800 mg/m 2 . At least three patients were treated at each dosage level. Patients could receive up to six courses in the absence of disease progression. MK-0752 therapy could be extended for up to 13 additional courses in patients with stable disease after six courses. The MTD was defined as the highest dose at which six patients had been treated with no more than one patient experiencing a DLT, and the next higher dose level was too toxic [22] . Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 4.0). Hematologic DLT was defined as any grade 4 neutropenia or thrombocytopenia. Nonhematologic DLT was defined as any grade 3 or 4 toxicity with the specific exclusion of grade 3 nausea or vomiting <5 days or responsive to antiemetics; grade 3 diarrhea responsive to antidiarrheal agents; grade 3 fever or infection <5 days; grade 3 hypophosphatemia, hypokalemia, or hypomagnesemia responsive to oral supplementation; or grade 3 ALT/AST elevation that returns to grade ≤1 prior to the next scheduled dose.
Pretreatment evaluations included a history, physical examination, performance status, disease evaluation, blood counts, electrolytes, renal and liver function tests, and a pregnancy test for females of childbearing age. Blood counts were obtained weekly during course 1, every 2 weeks during course 2, and before each subsequent course. History, physical examination, and serum chemistries were obtained weekly in course 1 and before each subsequent course. Disease evaluations were obtained at baseline, after course 2, and after every other course thereafter. Tumor response was reported as previously described [21] .
Pharmacokinetic studies
Blood samples (2 mL) were collected in heparinized tubes before the MK-0752 dose and at 1, 2, 3, 6, 8 (±2), and 24 (±4), and 48 h after dose 1, course 1. The plasma concentrations of MK-0752 were determined using a validated liquid chromatography tandem mass spectrometry method [23] .
The concentration-time data for MK-0752 was analyzed using noncompartmental techniques. For each set of serial PK samples, the peak plasma concentration (C max ) and time to C m a x (T m a x ) were determined from the plasma concentration-time profile. The log-linear terminal slope (β) was defined by the last two measurable concentration-time data points in the serial sampling window. Terminal half-life (t 1/2 ) was calculated as t 1/2 =ln (2)/β. The area under the plasma concentration versus time curve from time zero to the last measurable sampling time point (AUC 0-Tlast ) was calculated using the linear-up/log-down trapezoidal rule.
Notch receptor expression and signal activity
Expression of NOTCH1 (antibody #3608, Cell Signaling Technology, Danvers, MA), HES1 (#5702, Millipore, Billerica, MA), and HES5 (#5708, Millipore) was analyzed in pretreatment formalin-fixed paraffin-embedded tumor sections by immunohistochemistry (IHC) as described previously [21] . Expression of the cleaved NICD (#4147, Cell Signaling), HES1, and HES5 proteins in PBMCs were quantified by Western blot analysis before, and 8 and 24 h following, treatment with MK-0752. Changes in expression of NOTCH-cleaved forms and NOTCH pathway target genes were correlated with MK-0752 systemic exposure (e.g., C max and AUC).
Results
Patient characteristics
Ten patients, all eligible, were enrolled. One patient was inevaluable for toxicity due to study withdrawal during course 1. The median number of courses was 2 (range 1-10). Table 1 summarizes the characteristics of the eligible patients. The sponsoring company prematurely withdrew support for this study, focusing on adult combination studies with MK-0752. Table 3 summarizes all toxicities at least possibly attributable to MK-0752 in evaluable patients. Nondose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. There were no grade 4 toxicities.
Toxicities
Responses
No objective responses were reported. Prolonged SD (≥3 courses) was observed in two patients at 1000 mg/m 2 /week, one patient with myxopapillary ependymoma (10 courses) and one patient with CPC (6 courses).
Pharmacokinetics
After dose 1, course 1 of MK-0752, PK studies were obtained in seven patients receiving 1000 mg/m 2 and three patients receiving 1400 mg/m 2 . The median C max and T max (range) of MK-0752 for patients treated at 1000 mg/m 2 /week were 88.2 μg/mL (40.6 to 109 μg/mL) and 3.0 h (1 to 8.6 h), respectively. The median C max and T max (range) of MK-0752 for patients treated at 1400 mg/m 2 /week were 60.3 μg/mL (59.2 to 91.9 μg/mL) and 8.1 h (6.1 to 24.1 h), respectively. As depicted in Fig. 1 , the median (range) AUC 0-Tlast values for 1000 and 1400 mg/m 2 /week were 1860 μg/mL h (1400-2914 μg/mL h) and 1981 μg/mL h (1319-2397 μg/mL h). The median (range) t 1/2 observed in all ten patients was 21.7 h (9.8-42.2 h).
NOTCH1 and HES protein expression
Pretrial tumor samples were available from five patients, one each with CPC, myxopapillary ependymoma, anaplastic astrocytoma, primitive neuroectodermal tumor (PNET), and medulloblastoma. NOTCH1 expression was detected in three of five tumors; the myxopapillary ependymoma and medulloblastoma were immunonegative. The PNET had the greatest level of expression detected by IHC. All tumors displayed nuclear expression of HES1, with the lowest and highest percentages of positive nuclei detected in ependymoma (10 % of nuclei positive) and PNET (60-100 % of nuclei positive), respectively. Expression of HES5 was also less predominant in ependymoma (30 % of nuclei positive) and most pronounced in CPC and PNET (60-100 % of nuclei positive). These data suggest broad expression of the NOTCH signal pathway in several types of pediatric brain tumors.
We used Western blotting to measure expression of NICD1 in PBMCs to determine whether MK-0752 blocked NOTCH1 cleavage in vivo. PBMCs were obtained before and at 8 and 24 h post-MK-0752 in seven evaluable patients (four from 1000 mg/m 2 and three from 1400 mg/m 2 ) (Fig. 2) . NICD1 was readily detected in all PBMC pellets. NICD1 expression was decreased in five of seven (71 %) patients at 8 h post-MK-0752. Two with higher levels of NICD1 at 8 h post-MK-0752 included one each from the 1000 and 1400 mg/m 2 dose levels; NICD1 expression in the patient treated at 1400 mg/m 2 subsequently decreased below baseline at 24 h. NICD1 expression was decreased from baseline in six of seven patients at 24 h post-MK-0752, including all three treated at 1400 mg/m 2 ( Fig. 2) .
Discussion
We report a novel dosing schedule of MK-0752 in ten children with recurrent CNS tumors; the highest dose tested, 1400 mg/ m 2 , was biologically effective. Though the trial was not completed and an MTD not determined, MK-0752 was well tolerated, with only one DLT (fatigue) at 1000 mg/m 2 and none at 1400 mg/m 2 . Fatigue was seen less frequently than in adults Fig. 1 Box and whisker plot, 5th-95th percentile of MK-0752 AUC values by dosage from course 1, day 1 in the present study, and our previously published results [21] (noted by an asterisk) Fig. 2 Variability for NICD Expression in PBMCs of patients with refractory solid tumors receiving a 3-days-on/4-days-off schedule of MK-0752 [19] . Unlike in adult studies [19, 20] , dose-limiting diarrhea and GI toxicity were not observed in this study. As we speculated previously [21] , the lower incidence of diarrhea in this study may be attributable to concurrent glucocorticoid therapy, which may protect against intestinal goblet cell metaplasia induced by inhibition of NOTCH signaling [24] . Weekly administration of MK-0752 was better tolerated than the 3-days-on/4-days-off schedule of MK-7052 in children, in which dose-limiting elevations of AST and ALT prevented dose escalation beyond 260 mg/m 2 [21] . Though no objective responses were reported, two of nine patients had prolonged SD (6 and 10 cycles), proportionally more than that seen with the 3-days-on/4-days-off schedule of MK-0752 in children in which 2 of 17 evaluable patients experienced prolonged SD (3 and 4 cycles) [21] . However, one patient with prolonged SD in this study had a diagnosis of myxopapillary ependymoma, the natural history of which is more consistent with longer time to recurrence and thus may not indicate MK-0752 effect. In contrast, better responses were seen in adult glioma patients, including one CR >1 year in a patient with anaplastic astrocytoma (1800 mg once weekly) and SD >1 year in a patient with glioblastoma multiforme (4200 mg once weekly) [19] . Prolonged SD (≥4 cycles) was seen in 11 other patients at doses ranging from 600 to 3200 mg, including nine additional patients with glioma, lending credence to the ability of MK-0752 to cross the bloodbrain barrier and mitigate tumor growth. Objective responses and prolonged disease stabilization were also seen in adults with advanced breast cancer treated with MK-0752 (days 1-3) and docetaxel [20] . Of 30 evaluable patients, 9 and 11 exhibited PR and SD, respectively, though the authors acknowledge that responses could be secondary to docetaxel effect alone.
IHC analyses in our study confirmed high-level expression of NOTCH family genes in pediatric brain tumors. The highest baseline level of NOTCH expression was seen in PNET, compatible with relatively frequent amplification of the region containing NOTCH2 in embryonal brain tumors [14, 25] . We detected target inhibition of NICD1 at 24 h post-MK-0752 treatment in PBMCs from six of seven patients for whom sample was available, including all three patients at 1400 mg/m 2 /week. In the adult phase I study, target inhibition was seen at weekly MK-0752 doses from 1800 to 4200 mg, corresponding to 1040 to 2400 mg/m 2 . Though we recommend a biologically effective dose of 1400 mg/m 2 /week, it is possible that greater and more prolonged target inhibition may be observed at higher dose levels, which warrants further study. Data from healthy adults suggest once weekly dosing of MK-0752 decreases expression of NOTCH pathway genes for at least 96 h [26] . In general, we found a dose-dependent decrease in NICD expression in PBMCs at 24 h after the higher dose (1400 mg) of MK-0752. Our longest pharmacodynamic time point of 24 h limits our assessment of the true duration of target inhibition with weekly MK-0752, though our study is more informative than the adult phase I study, which only evaluated target inhibition in hair follicles collected 4-6 h posttreatment [19] .
MK-0752 exhibits linear pharmacokinetics based on a comparison of the median AUC 0-Tlast for 1000 and 1400 mg/ m 2 and our prior results, which investigated 200 and 260 mg/ m 2 on the 3-days-on/4-days-off schedule (Fig. 1) . The median t 1/2 (21.7 h) in this study is longer than 11.4 h from our previously published results [21] . A phase I study in adults with advanced solid tumors reported PK values for weekly MK-0752 at numerous dose levels. The t 1/2 of 21.7 h observed in the present study is longer than 13.8 and 16.2 h reported in adults given doses of 1800 (∼1040 mg/m 2 ) and 2400 mg (∼1400 mg/m 2 ), respectively. The geometric mean C max in children receiving 1000 mg/m 2 in the present study is 75.2 μg/mL, which is similar to 84.2 μg/mL reported in adults receiving 1800 mg (∼1040 mg/m 2 ), suggesting similar MK-0752 exposure when given weekly in children and adults [19] .
Crosstalk between NOTCH and other important cancer signaling pathways provides an avenue by which rational combination of targeted agents may potentiate the effect of MK-0752 or other gamma-secretase inhibitors in development (e.g., RO4929097 and PF-03084014). NOTCH influences a number of signaling pathways in a contextdependent manner, including several that are strongly implicated in pediatric brain tumors, such as Wnt/TCF [27, 28] , SHH [29] , RAF/RAS/MEK/ERK [30] , and PI3K/Akt/ mTOR [31] ; the latter holds the greatest potential for rapid clinical translation. Zhao et al. demonstrated strong positive regulation of NOTCH1 on Akt/mTOR pathways in glioblastoma cells in vitro [32] . RNA interference of NOTCH1 diminished phosphorylated Akt and suppressed downstream activation of mTOR, inhibiting glioblastoma cell growth and inducing caspase-mediated apoptosis. Jin et al. further exemplified the interplay of these pathways by evaluating the individual and combined effects of MRK003, a less potent preclinical analog of MK-0752, and Akt inhibitor MK-2206 in glioblastoma cell lines [33] . Combination treatment demonstrated synergistic inhibition of the migratory and invasive potential of glioblastoma and enhanced inhibition of Akt phosphorylation compared to monotherapy. An adult study investigating the combination of mTOR inhibition (Ridaforolimus) with MK-0752 is ongoing (NCT01295632). Multiple inhibitors of the Akt/mTOR pathway have been deemed tolerable and effective in children [34, 35] , leaving open the possibility of investigating this combination in the pediatric population.
Overexpression of NOTCH receptors and targets has been associated with chemotherapy resistance in solid tumors [28, 36] , suggesting utility for gamma secretase inhibition in combination with conventional chemotherapeutic agents. Though resistance is not common in newly diagnosed brain tumors, recurrent tumors are notoriously more resistant to standard therapy. McAuliffe et al. demonstrated Notch-mediated cisplatin resistance in an ovarian carcinoma xenograft model, which was overcome by siRNA NOTCH inhibition [37] . Groeneweg et al. reported synergy between MRK-003 (analog of MK-0752) and paclitaxel in a platinum-resistant ovarian carcinoma xenograft model [38] . Hiddingh et al. also demonstrated the ability of NOTCH inhibition to induce temozolomide sensitivity in glioblastoma in vitro and in vivo [39] , work which led to an ongoing clinical trial of gammasecretase inhibitor RO4929097 and temozolomide in adult patients with glioblastoma (NCT01119599).
This study demonstrates tolerability, favorable pharmacokinetics, and target inhibition of weekly MK-0752 in children with recurrent brain tumors at both dose levels studied. The study was prematurely closed due to industry support withdrawal; however, MK-0752 was well tolerated at the highest dose level tested (1400 mg/m 2 weekly), and target inhibition in PBMCs was uniformly noted, suggesting that a biologically effective dose was achieved. In contrast to the lack of objective responses reported in this study, objective responses were reported in adults with gliomas receiving doses in a similar range once weekly, including several with aggressive phenotypes [19] . Preclinical work highlighting complex interactions between NOTCH and other cancer pathways suggests that gamma-secretase inhibitors, such as MK-0752, in combination with targeted agents (e.g., mTOR/Akt inhibitors), or chemotherapeutic agents (e.g., temozolomide) could be explored in phase I trials.
